Aligos Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2018 | — | $-13.7M | $24.5M |
| Jun 2019 | — | $-33.4M | — |
| Sep 2019 | — | $-47.0M | $21.1M |
| Dec 2019 | — | $-64.9M | $69.6M |
| Mar 2020 | — | $-83.9M | $25.4M |
| Jun 2020 | — | $-104.6M | $22.7M |
| Sep 2020 | — | $-136.7M | $31.8M |
| Dec 2020 | — | $220.0M | $220.4M |
| Mar 2021 | — | $195.2M | $200.4M |
| Jun 2021 | — | $168.9M | $187.7M |
| Sep 2021 | — | $217.0M | $239.7M |
| Dec 2021 | — | $184.7M | $186.8M |
| Mar 2022 | — | $152.9M | $104.6M |
| Jun 2022 | — | $137.0M | $71.2M |
| Sep 2022 | — | $122.0M | $86.4M |
| Dec 2022 | — | $103.9M | $81.3M |
| Mar 2023 | — | $84.8M | $78.7M |
| Jun 2023 | — | $69.6M | $90.8M |
| Sep 2023 | — | $54.8M | $70.4M |
| Dec 2023 | — | $92.1M | $135.7M |
| Mar 2024 | — | $59.8M | $24.2M |
| Jun 2024 | — | $67.2M | $45.1M |
| Sep 2024 | — | $50.1M | $35.3M |
| Dec 2024 | — | $-29.0M | $37.0M |
| Mar 2025 | — | $116.4M | $73.8M |
| Jun 2025 | — | $101.9M | $18.7M |
| Sep 2025 | — | $71.8M | $41.9M |
| Dec 2025 | — | $53.5M | $18.3M |
| Mar 2026 | — | $31.8M | $30.0M |
| Jun 2026 | — | $31.9M | $30.4M |